Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 14/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440447 | 0.92 | RORC (0.44) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16440408 | 0.92 | RORC (0.45) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL18602943 | 0.92 | RORC (0.45) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16434401 | 0.92 | RORC (0.45) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16440404 | 0.92 | RORC (0.44) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16437830 | 0.92 | RORC (0.49) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16440418 | 0.90 | RORC (0.48) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16440412 | 0.90 | RORC (0.49) | RORCKMT2AMEN1LMNAPRKACA | |
| SCHEMBL16434428 | 0.89 | RORC (0.44) | RORCKMT2AELOVL1MEN1LMNA | |
| SCHEMBL16440443 | 0.89 | RORC (0.47) | RORCKMT2AELOVL1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9499533-B2 | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity | SHIONOGI & CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | RORC 870/4885KMT2A 1257/4885ELOVL1 4633/4885 |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | RORC 870/4885KMT2A 1257/4885ELOVL1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.